A decision on whether to open a costly cancer drug to generic competition will be made shortly. It doesn’t require congressional approval.
corporate power
Posted inEconomic Policy
Big Business Games the Supply Chain
The disruptions, and the subsequent circumventions, have accelerated Amazon and Walmart’s takeover at the expense of independent retailers.
Posted inHealth and Social Policy
Making the Next Coronavirus Vaccine Truly Public
The vaccine developed at the Walter Reed Army Institute should not be privatized for maximum profit.
Posted inPolitics
Inflation-Fighting Legislative Agenda Takes Shape
An ocean shipping regulatory bill got attached to a broader reshoring bill. There’s now an emerging bipartisan agenda to dismantle misguided, corporate-friendly policies.
Posted inEconomic Policy
Why Trucking Can’t Deliver the Goods
The yearly turnover rate among long-haul truckers is 94 percent. And you wonder why you’re not getting your orders on time?
Posted inMoney, Politics, and Power
Rollups: The Big Tech Monopoly Down on the Farm
John Deere refuses to allow farmers to repair their own equipment. That’s because it wants to control farm technology and data, critics contend.
Posted inEconomic Policy
How America’s Supply Chains Got Railroaded
Rail deregulation led to consolidation, price-gouging, and a variant of just-in-time unloading that left no slack in the system.
Posted inEconomic Policy
We Were Warned About the Ports
A 2015 federal report predicted the entire slowdown that’s come to pass.
Posted inMoney, Politics, and Power
Jon Ossoff’s Moment of Trust
Before entering the Senate, Ossoff had more than half his net worth in Apple stock; it’s now in a blind trust. Today, he must vote on legislation affecting the company.
